FIELD: medicine.
SUBSTANCE: described humanised and chimeric CD20 antibodies are designed for treatment of CD20-positive malignant and autoimmune diseases. Antibody is effective with respect to depletion of B-cells of mammals in vivo, contains in variable region of H-chain of CDR3- sequence from antibody to human CD20 and practically all remains of consensus frame region (FR) of human H-chain of subgroup 111. According to invention antibody is used in composition or product, binding CD20. Besides, antibody is used for apoptosis induction, treatment of CB20-positive cancer, autoimmune disease, and rheumatic arthritis. Invention contains nucleic acid (NA) coding antibody, expression vector containing specified NA, and host cell producing recombinant antibody, as well as method of specified antibody production. According to invention antibodies are characterised by minimum antigenicity or no antigenicity at all, that enables to use them for continuous treatment overcoming limits of existing therapeutic compositions application.
EFFECT: enables to use for continuous treatment.
83 cl, 32 dwg, 12 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING VASCULITIS | 2005 |
|
RU2411956C2 |
| METHOD OF TREATING MULTIPLE SCLEROSIS | 2005 |
|
RU2384345C2 |
| METHOD OF TREATING JOINT INJURIES | 2006 |
|
RU2457860C2 |
| COMPOSITIONS OF ANTIBODIES | 2005 |
|
RU2426554C2 |
| METHOD FOR TREATING MULTIPLE SCLEROSIS | 2015 |
|
RU2757961C2 |
| METHOD AND COMPOSITION FOR REDUCTION OF MICROMOLECULE AGGREGATION UNDER PHYSIOLOGICAL CONDITIONS | 2009 |
|
RU2563823C2 |
| HUMANISED CD19 ANTIBODIES AND USING THEM FOR TREATING TRANSPLANTATION-RELATED ONCOLOGICAL AND AUTOIMMUNE DISEASE | 2007 |
|
RU2495882C2 |
| AFFINITY-MATURED HUMANISED ANTI-CEA MONOCLONAL ANTIBODIES | 2010 |
|
RU2570554C2 |
| APOPTOTIC ANTIBODIES AGAINST IgE | 2008 |
|
RU2500686C2 |
| COMBINED THERAPY BASED ON AFUCOSYLATED CD20 ANTIBODY IN COMBINATION WITH CD22 ANTIBODY CONJUGATE - DRUG PREPARATION | 2014 |
|
RU2700092C2 |
